CJC-1295 (without DAC)
Short-Acting Growth Hormone Releasing Hormone Analog | Modified GRF 1-29
On this page
What is CJC-1295 (without DAC)?
CJC-1295 (without DAC) is a lab-made analog of growth hormone-releasing hormone (GHRH), the body's natural signal that tells the pituitary gland to release growth hormone in bursts. Because this version clears the body quickly, researchers study it for restoring that natural, pulsatile release pattern rather than a sustained one. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
CJC-1295 (without DAC) is a synthetic ghrh analog (mod grf 1-29).
CJC-1295 without DAC — also called Modified GRF 1-29, or Mod GRF 1-29 — is a lab-made version of growth hormone releasing hormone (GHRH), the body's own signal for releasing growth hormone. This short-acting form prompts growth hormone to come out in bursts, much like the body's natural pattern. Its half-life is only about 30 minutes, far shorter than the DAC-modified version. Researchers note that the short window allows finer control over each growth hormone pulse and lowers the chance that the receptor stops responding.
Key research areas
- Preserves natural GH pulsatility
- Minimal side effects
- No receptor desensitization
- Precise control over GH release
Researched dosing
This table reflects how researchers structure study designs with CJC-1295 — the dose ranges and schedules used in published research, presented as methodology reference, not usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Longevity studies | 100mcg | 2x daily (morning and bedtime) | Subcutaneous |
| Body-composition studies | 100-150mcg | 3x daily (morning, post-workout, bedtime) | Subcutaneous |
| Highest-dose GH-release studies | 200mcg | 2-3x daily with GHRP | Subcutaneous |
| Sleep studies | 100-200mcg | Once at bedtime | Subcutaneous |
Commonly cycled 16 weeks on, 4+ weeks off.
How it works
At the cell level, CJC-1295 research looks at how the peptide binds GHRH receptors on the pituitary gland, prompting a burst of growth-hormone release similar to the body's own signaling pattern.
Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses
Molecular data
These figures — molecular weight, amino-acid sequence, chain length — are the chemistry basics researchers use to confirm a CJC-1295 sample's identity and purity.
- Weight
- 3367.97 Da
- Length
- 30 amino acids
- Type
- GHRH analog (Mod GRF 1-29)
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys
Pharmacokinetics
This chart shows how quickly a research dose of CJC-1295 clears the body — notice the timescale is minutes, not days, which is why this version is studied for short, pulsatile GH release rather than sustained elevation.
- Peak
- 0.25 hr
- Half-life
- 0.5 hrs
- Cleared
- ~2.5 hrs
Teichman et al. 2006
Research applications
This section lists the research areas scientists have studied for CJC-1295 — a summary of what's been investigated in the literature, not medical claims about people.
Growth Hormone
Stimulates physiological growth hormone pulses that decline with age. Increases insulin-like growth factor 1 levels through enhanced GH secretion. Maintains healthy pituitary-somatotroph axis without suppression.
Longevity
Supports longevity through restoration of natural GH pulsatility and IGF-1 elevation, improving body composition and tissue repair.
Recovery
Supports recovery from exercise and injury through enhanced growth hormone secretion and IGF-1 levels.
Dosage reference
- Doses used in research
- 100 mcg per research dose (10 units at the common 100 mcg / 10 unit mixing ratio)
- Frequency in studies
- 2-3 times daily for pulsatile release
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- GH elevation within 30 minutes, IGF-1 increases in 2-4 weeks, body composition changes in 6-12 weeks
- Storage
- Refrigerate immediately, use within 30 days of reconstitution
- Cycle length
- 12-16 weeks continuous use
- Break between cycles
- Optional 2-4 week breaks to assess baseline
Interactions
This list shows which other growth-hormone-research peptides are studied alongside CJC-1295, and why they're often paired in published protocols.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried CJC-1295 powder into a liquid research solution.
- Allow vial to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab and allow to dry
- Calculate required bacteriostatic water volume using the calculator below
- Draw calculated volume of bacteriostatic water into syringe
- Inject water slowly down the inside wall of the vial (never directly onto powder)
- Gently swirl until powder completely dissolves (never shake)
- Solution should be clear - discard if cloudy or contains particles
Lyophilized: Room temperature, stable for 2 years if stored properly, use within 2 years
Reconstituted: 2-8°C, use within 30 days
Open the CJC-1295 reconstitution calculatorQuality indicators
These are the checks researchers and lab-report reviewers use to confirm a CJC-1295 sample is pure and correctly identified before it goes into a study.
Legitimate source with COA - Purchase from vendors providing certificates of analysis showing >98% purity
Proper cold chain shipping - Peptide should arrive with ice packs or refrigerated shipping in hot weather
Vacuum-sealed vials - Legitimate peptides create vacuum when reconstituted - water should be pulled in
Check expiration dates - Lyophilized peptide typically stable for 2 years if stored properly
Pre-mixed solutions - Avoid pre-reconstituted products - peptide degrades rapidly in solution
Discolored powder - White to off-white powder only - yellow or brown indicates degradation
What to expect
This timeline summarizes what the research literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Improved sleep quality, vivid dreams common due to enhanced REM sleep
Increased recovery from workouts, reduced DOMS, better pumps
Noticeable improvements in skin quality, minor body composition changes
More significant lean mass gains, fat reduction, improved joint comfort
Continued gradual improvements in body composition and well-being
Safety notes
This section covers handling cautions and regulatory notes for CJC-1295 — research-use-only scope, not medical safety advice for people.
- Not recommended for those with active cancer due to growth-promoting effects
- Avoid if you have diabetic retinopathy or severe kidney disease
- Monitor blood glucose if diabetic - GH can affect insulin sensitivity
- Not FDA approved
- Generally well-tolerated with minimal side effects at recommended doses
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
No significant adverse effects on pituitary morphology or function with chronic use, supporting the safety of long-term pulsatile GHRH analog administration.
Found CJC-1295 without DAC had 4x greater receptor affinity than native GHRH and enhanced resistance to enzymatic degradation, a proposed explanation for its greater reported efficacy.
Showed preservation of natural GH pulsatility patterns when administered 3 times daily, with no evidence of pituitary desensitization over the study period.